Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming Soon – October 2019
Rituximab-based chemoimmunotherapy regimens (e.g., R-DHAP, R-ICE, R-ESHAP) are the standard of care for relapsed / refractory (R/R) DLBCL, followed by conditioning and ASCT in eligible patients. The CAR T-cell therapies Yescarta and Kymriah have expanded treatment options, although their use is restricted to third and subsequent lines of therapy. In 2018, Keytruda was the first immune checkpoint inhibitor to gain approval in NH L, specifically for R/RPMBCL, a rare subset of DLBCL. Despite the evolving market landscape, significant unmet need remains in R/RDLBCL owing to the limited availability of effective treatment options.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S hematologist-oncologists and 30 European hematologist-oncologists
Key companies: Kite Konnect, Novartis, Merck & Co.
Key drugs: Rituximab, Yescarta, Kymriah, Keytruda
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Already a Client? Log in to access this report.